Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Exelixis, Genomic Health Inc, Novartis Pharmaceuticals Corporation, and Taiho Oncology.

Community Practice Connections™: 3rd Annual School of Nursing Oncology™

Release Date: September 30, 2019
Expiration Date: September 30, 2020
Media: Internet - based

Activity Overview

Oncology nursing is a perpetually evolving field, and staying up-to-date with the latest advances is key to providing the best care to your patients. Advancements in the pharmacologic treatment of cancer, therapies to help mitigate disease symptoms, and new options for managing treatment-related adverse events are emerging at a rapid pace. So you can continue to deliver the highest-quality care, our expert faculty will provide the latest information on key topics in oncology that can readily be applied to your practice. They will discuss strategies to help you optimize patient management and provide insight into the evolving treatment landscape for a variety of malignancies that you may encounter.

Barriers to the optimal delivery of care for patients with cancer are common, and this activity is designed to answer critical questions in a manner that will help you to overcome those barriers. This online enduring activity highlights several of the key topics covered at the 3rd Annual School of Nursing Oncology™, a 2-day conference held each year. This online activity covers supportive care strategies relevant to lung cancer, melanoma, and genitourinary cancers, as well as oncology at large. Additionally, key updates in new treatments are addressed.

Benefits of Participating

  • Get up-to-date on the most recent advances in therapeutic strategies for the treatment of lung cancer, melanoma, prostate cancer, and renal cell carcinoma.
  • Learn supportive care strategies for common concerns of patients with cancer, including chemotherapy-induced nausea and vomiting and bone metastases and pain.
  • Hear from expert oncology nursing specialists regarding how they apply new data to optimize patient care.
  • Gain an overview of ongoing clinical trials and strategies to counsel your patients regarding clinical trial participation.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Exelixis, Genomic Health Inc, Novartis Pharmaceuticals Corporation, and Taiho Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward nurses interested in the management of patients with cancer. Other healthcare professionals interested in the management of patients with cancer are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Summarize recent therapeutic advancements for patients with solid and hematologic malignancies.
  • Outline the roles of different assays in guiding treatment selection for patients with cancer.
  • Identify common treatment-related adverse events for different malignancies.
  • Demonstrate awareness of best practices to manage and counsel patients concerning adverse events associated with therapies they receive to treat their cancer.
  • Select evidence-based supportive care strategies for patients throughout the continuum of cancer management.
  • Analyze elements of clinical trial design in the context of enhancing patient communication and clinical trial enrollment.

Faculty, Staff, and Planners’ Disclosures


Grace Cherry
Grace Cherry, RN, MSN, NP
Oncology Nurse Practitioner
UCLA Melanoma Program
Los Angeles, CA

Disclosures: Consultant: Array; Speakers Bureau: Merck, Novartis.

Beth Eaby-Sandy
Beth Eaby-Sandy, MSN, CRNP
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Speakers Bureau: Takeda, AstraZeneca, Helsinn, Merck

Laura S. Wood
Laura S. Wood, RN, MSN, OCN
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Center
Cleveland, OH

Disclosures: Consultant: Eisai; Speakers Bureau: Bristol-Myers Squibb, Merck, Pfizer.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By